37th week of 2010 patent applcation highlights part 45 |
Patent application number | Title | Published |
20100233674 | Cells for detection and production of influenza and parainfluenza viruses - The invention provides cell lines that are useful for the rapid detection and production of influenza and parainfluenza viruses. In particular, the invention relates to transgenic cells with increased sensitivity to infection by influenza A, influenza B, or parainfluenza 3 viruses, or which are capable of enhanced productivity of infectious virions. The invention is suitable for use in culturing clinical influenza and parainfluenza virus isolates and for the production of influenza and parainfluenza virus for vaccine formulations, as antigen preparations for diagnostic applications, and for screening antiviral drugs. | 2010-09-16 |
20100233675 | ANALYTE MANIPULATION AND DETECTION - Provided is a method for separating two or more analytes in a fluid, which method comprises: (a) binding each different analyte to a different functional particle in one or more binding zones, to produce two or more bound analytes; (b) allowing the bound analytes to move through a separating conduit to two or more separate functional zones; wherein, each different functional particle has, or can be controlled to have, a different function in the fluid as compared with the other functional particles; and wherein the separating conduit separates into two or more functional conduits, such that the separating conduit serves to separate the bound analytes into the separate functional conduits by means of the different functions of the different functional particles. Also provided is an apparatus for separating two or more analytes in a fluid, which apparatus comprises: (a) a binding zone; (b) two or more functional conduits; (c) a separating conduit connecting the binding zone to the two or more functional conduits; (d) a transporter for transporting the analyte through the separating conduit from the binding zone to the two or more functional conduits; and (e) optionally one or more concentrating zones in connection with at least one of the functional conduits. | 2010-09-16 |
20100233676 | HIGH AFFINITY FLUOROCHROME BINDING PEPTIDES - The present invention contemplates strategies comprising small molecule, cell permeable probes that allow site-specific protein labeling for visualizing biological processes. In one embodiment, the present invention contemplates a series of short peptide sequences comprising high affinity binding (i.e., for example, subnanomolar affinity (0.53 nM) for indocyanine fluorochromes. In one embodiment, the peptide sequences comprise a 5 pmol detection limit for indocyanine fluorochromes. In one embodiment, the present invention contemplates methods comprising high affinity peptide-fluorochrome binding pairs in biological applications including, but not limited to, enzyme linked immunoabsorbent assay (ELISA), fluorescence activated cell sorting (FACS), microscopy (i.e., for example scanning electromicroscopy), Western Blots, histochemistry, protein and cell based tracking both in vitro and in vivo. | 2010-09-16 |
20100233677 | FULL GENOME SEQUENCES OF HUMAN RHINOVIRUS STRAINS - Infection by human rhinovirus (HRV) causes upper and lower respiratory tract disease with varying degrees of virulence. The molecular basis of diversity was examined by completing the genome sequences for all known serotypes (n=99) as well as novel field samples. Superimposition of capsid crystal structure and optimal-energy RNA configurations established the alignments. The phylogeny revealed conserved motifs, Glade-specific diversity including a potential new species (clade-D), pan-genome mutations in field isolates, and unexpected recombination that contributes to heterogeneity. A spacer tract near a 5′-UTR cloverleaf was hypervariable, and in analogy with poliovirus, may be associated with virulence. A previously unidentified configuration consistent with non-scanning internal ribosome entry may account for rapid protein translation. The data density from complete sequences of the HRV reference serotypes provided high resolution for this degree of modeling, and serves as a platform for full genome-based epidemiologic studies, for viral diagnostics and prognostics, and for antiviral compounds and vaccines. | 2010-09-16 |
20100233678 | TUNABLE AFFINITY LIGANDS FOR THE SEPARATION AND DETECTION OF TARGET SUBSTANCES - Conformationally tunable affinity ligands are rationally designed and selected for the ability to switch under operator-defined environmental conditions between or among structurally distinct states that have different affinities for a given target substance. Tunable affinity ligands are incorporated into reagents, separation media, assays, sensors, devices, kits and systems for sorting, separating, detecting, sensing, quantifying, identifying and monitoring target substances. Applications include biomedical research, diagnostics, drug discovery, bioproduction and processing and environmental, industrial, chemical, agricultural and military use. | 2010-09-16 |
20100233679 | DETECTION OF TRUNCATION MUTATIONS IN A LARGE BACKGROUND OF NORMAL DNA - Various methods and strategies are disclosed for detecting human tumors, and specifically colorectal tumors. Methods are also disclosed for detecting truncation mutations in a large background of wild-type DNA. And, methods for detecting AP mutations in a large background of wild-type DNA are also disclosed. | 2010-09-16 |
20100233680 | Gene Expression Profiles and Methods of Use - The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and methods of using expression profiles and microarrays. The invention also provides methods and compositions for diagnostic assays for detecting cancer and therapeutic methods and compositions for treating cancer. The invention also provides methods for designing, identifying, and optimizing therapeutics for cancer. | 2010-09-16 |
20100233681 | METHOD FOR CELL BASED ASSAYS - Disclosed is a method for cell storage on beads and subsequent utilisation of cryogenically stored cells in cellular assays. | 2010-09-16 |
20100233682 | FLUID PROCESSING AND VOLUME DETERMINATION SYSTEM - A fluid processing system is described having at least two chambers. Each of said chambers is separated in a first and a second part by a flexible membrane, the first part, in use, comprising essentially a gas and the second part, in use comprising essentially a non-gaseous fluid, an inlet and/or an outlet means. One or more channels are provided connecting said second parts of said at least two chambers, wherein at least one of said one or more channels includes a pressure sensitive one-way valve. Further, means for exerting pressure on said first part of at least one of said at least two chambers is provided to allow transfer of a sample liquid. | 2010-09-16 |
20100233683 | AMPLIFICATION OF DNA FRAGMENTS - A method for detecting a nucleic acid molecule having a target sequence adjacent a 3′ terminus is provided. Also provided is a method for differentiating nucleic acid molecules having a target sequence adjacent a 3′ terminus from nucleic acid molecules in which the same sequence is embedded within the molecule. | 2010-09-16 |
20100233684 | METHOD FOR DETERMINING INFLAMMATORY DISEASE - It is an object of the present invention to provide a method for determining inflammatory diseases including myocardial infarction as a typical example, which involves identifying polymorphisms associated with myocardial infarction and using the gene polymorphisms, an oligonucleotide that can be used for the method, a kit for diagnosing inflammatory diseases, a therapeutic agent for inflammatory diseases, and the like. The present invention provides a method for determining an inflammatory disease, which comprises detecting at least one type of gene polymorphism existing in a proteasome subunit α type 6 gene. | 2010-09-16 |
20100233685 | Two-Color Fluorescent Reporter for Alternative Pre-MRNA Splicing - The present invention provides reporter constructs for in vivo or in vitro monitoring of alternative pre-mRNA splicing events. The reporter constructs described herein are also particularly useful for high-throughput screening of compounds that affect alternative pre-mRNA splicing. Kits comprising the reporter constructs of the present invention find utility in a wide range of applications including, for example, basic research, drug screening, and drug design. | 2010-09-16 |
20100233686 | Multiplex Quantitative Nucleic Acid Amplification and Melting Assay - The invention is a single-tube multiplex assay, capable of simultaneously amplifying, detecting and quantifying multiple nucleic acid targets, using multiple hybridization probes, labeled with the same fluorescent reporter label, but each having a distinct melting temperature. The assay can be further multiplexed with the use of multiple sets of hybridization probes, each set labeled with a separate fluorescent reporter label. | 2010-09-16 |
20100233687 | METHOD AND SYSTEM FOR TEMPERATURE CORRECTION IN THERMAL MELT ANALYSIS - The present invention relates to methods and systems for temperature correction in thermal melt analysis. More specifically, embodiments of the invention relate to the correction of the melting temperature (T | 2010-09-16 |
20100233688 | METHOD FOR DIAGNOSING SPINAL MUSCULAR ATROPHY - A method for diagnosing spinal muscular atrophy is provided. The method includes providing a biological sample of a subject containing a nucleotide of SMN gene, amplifying SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a universal multiplex PCR using the nucleotide as a template and the primers to obtain fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8, labeling the fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a fluorescent primer to obtain fluorescence-labeled exon fragments, and analyzing the fluorescence-labeled exon fragments by a capillary electrophoresis. If the SMN1/SMN2 ratios in exon 7 and 8 are different, it indicates that the subject is susceptible to spinal muscular atrophy. Additionally, if the peak of certain exon fragment appears crossed, it indicates an intragenic mutation in the exon. | 2010-09-16 |
20100233689 | PYRAZOLOANTHRONE AND DERIVATIVES THEREOF FOR THE TREATMENT OF CANCER EXPRESSING 'MULLERIAN INHIBITING SUBSTANCE' TYPE II RECEPTOR (MISRII) AND OF EXCESS ANDROGEN STATES - The present invention relates to pyrazoloanthrones or functional derivatives or functional analogues thereof to activate MIS receptor-mediated downstream effects in a cell. In particular, the present invention relates to method to prevent and treat cancer that expresses MIS receptor type II (MISRII) by administering to a subject at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen, whereby the subject is administered at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect provides pharmaceutical compositions comprising at least one pyrazoloanthrone or functional a derivative or a functional analogue thereof, and optionally with one or more additional agents such as chemotherapeutic agents. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with a pyrazoloanthrone or a functional derivative or a functional analogue thereof that lowers the effective dose of the chemotherapeutic agent, such as for example, paclitaxel. | 2010-09-16 |
20100233690 | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer - The invention relates to the use of inhibitors of the expressed proteins of the murine genes and/or their human homologues listed in Table 1 for the preparation of a therapeutical composition for the treatment of cancer, in particular for the treatment of solid tumors of lung, colon, breast, prostate, ovarian, pancreas and leukemia and the use of the genes listed in Table 1 for the diagnosis of cancer. The invention also relates to the therapeutical compositions comprising the inhibitors and to methods for development of the inhibitor compounds. | 2010-09-16 |
20100233691 | Gene Expression Profiling for Identification, Monitoring and Treatment of Prostate Cancer - A method is provided in various embodiments for determining a profile data set for a subject with prostate cancer or conditions related to prostate cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-4. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 2010-09-16 |
20100233692 | FLUORESCENTLY LABELED FUSION PROTEIN FOR ASSAYING ADENOSINE TRIPHOSPHATE - The object of the present invention is to provide a substance, which is easy to handle and enables the measurement of ATP with a high sensitivity regardless of the concentration of protein, and further a measuring method of ATP using the substance. Such object is solved with a fluorescence labelled fusion protein obtained by attaching two types of fluorescent substances of potential donor and acceptor for fluorescence resonance energy transfer (FRET) respectively to a protein which can cause structural changes depending on ATP binding, namely ε protein, which is the subunit of ATP synthetase, and further solved by contacting the fluorescence labelled fusion protein with a subject substance and then measuring the fluorescence spectra. | 2010-09-16 |
20100233693 | METHODS FOR DIAGNOSING, PROGNOSING, OR THERANOSING A CONDITION USING RARE CELLS - The invention encompasses methods for diagnosing, theranosing, or prognosing a condition in a patient based on the results of one or more analysis methods. The methods can comprise enriching a sample obtained from the patient for one or more rare cells. The analysis methods can include performing enumeration of the one or more rare cells or cell subtypes, performing nucleic acid analysis, or detecting a serum marker. | 2010-09-16 |
20100233694 | DEVICES AND METHODS FOR DIAGNOSING, PROGNOSING, OR THERANOSING A CONDITION BY ENRICHING RARE CELLS - The invention encompasses methods and devices for diagnosing, theranosing, or prognosing a condition in a patient by enriching a sample in rare cells. The devices can be a microfluidic device comprising an array of obstacles and one or more binding moieties. The devices and methods can allow for enrichment of cells based on size and affinity, recovery of cells in locations on the microfluidic device, release of cells from the microfluidic device, flow of sample through the microfluidic device, and retention of rare cells from a sample obtained from a patient having a condition. | 2010-09-16 |
20100233695 | MOLECULAR DIAGNOSIS AND TYPING OF LUNG CANCER VARIANTS - Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and/or proteins that are selectively expressed at a high or low level in certain tumor subtypes. Biomarker expression can be assessed at the protein or nucleic acid level. | 2010-09-16 |
20100233696 | METHODS, FLOW CELLS AND SYSTEMS FOR SINGLE CELL ANALYSIS - A method, flow cell and/or device for increasing the recovery of a limiting analyte in a sample, e.g., for single molecule analysis is disclosed. Methods for preparing a nucleic acid sample from a single cell and capturing nucleic acids on a surface configured for use in or with single molecule analysis are also provided. | 2010-09-16 |
20100233697 | METHOD FOR STANDARIZING SURFACE BINDING OF A NUCLEIC ACID SAMPLE FOR SEQUENCING ANALYSIS - Methods are described which enable nucleic acid sample standardization prior to anchoring to a surface, especially useful in single molecule nucleic acid sequencing applications when sample is limiting or unamplified. | 2010-09-16 |
20100233698 | APPARATUS AND METHOD FOR MULTIPLEX ANALYSIS - The present invention provides miniaturized instruments for conducting chemical reactions where control of the reaction temperature is desired or required. Specifically, this invention provides chips and optical systems for performing and monitoring temperature-dependent chemical reactions. The apparatus and methods embodied in the present invention are particularly useful for high-throughput and low-cost amplification of nucleic acids. | 2010-09-16 |
20100233699 | PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS - The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR. | 2010-09-16 |
20100233700 | UBIAD1 GENE AND HYPERLIPIDEMIA - The disclosure relates to genetic mutations in UBIAD1 gene that segregate with Schnyder's crystalline corneal dystrophy. The disclosure provides methods for detecting such mutations as a diagnostic for Schnyder's crystalline corneal dystrophy either before or after the onset of clinical symptoms. Also provided are screening methods for identifying medical conditions related to cholesterol metabolism, including atherosclerosis, risk of future loss of vision, and future need for corneal transplantation. | 2010-09-16 |
20100233701 | Use of non-clonal chromosomal aberrations for cancer research and clinical diagnosis - A diagnostic method of determining tumorigenicity of a tissue specimen includes the steps of determining the magnitude of genome diversity in the tissue specimen, and diagnosing a likelihood of cancer in response thereto. The magnitude of genome diversity includes the determination of karyotypic heterogeneity in tissue specimen, illustratively by detecting non-clonal chromosome aberrations (NCCAs). The detection of NCCAs includes the identification of various types and frequency of NCCAs, and diagnosis is responsive to the step of detecting the frequency of NCCAs. Detection of NCCAs includes the further step of screening lymphocytes. Also, the step of determining the presence of elevated genome diversity includes the step of applying Spectral Karyotyping to detect structural and numerical aberrations throughout the genome. The diagnostic method is useful to determine drug resistance in a patient and potential harmfulness, to evaluate the side effects of drugs, and to measure genome system stress. | 2010-09-16 |
20100233702 | METHOD TO PREDICT RESPONSE TO TREATMENT FOR PSYCHIATRIC ILLNESSES - The disclosure provides methods and compositions useful for identifying a subject's predisposition to lithium treatment. | 2010-09-16 |
20100233703 | EMX2 IN CANCER DIAGNOSIS AND PROGNOSIS - The present invention provides methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. The methods generally involve determining a normalized expression level of an EMX2 gene product, which correlates with prognosis and likelihood of survival. | 2010-09-16 |
20100233704 | METHODS OF DETECTING LUNG CANCER - Methods of lung cancer in a sample from a patient are provided. Methods of detecting changes in expression of one or more target RNAs associated with lung cancer are also provided. Compositions and kits are also provided. | 2010-09-16 |
20100233705 | METHOD OR SYSTEM USING BIOMARKERS FOR THE MONITORING OF A TREATMENT - The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy. | 2010-09-16 |
20100233706 | METHODS TO FIX AND DETECT NUCLEIC ACIDS - In one aspect, the invention relates to a method for fixing a short nucleic acid in a biological sample. In another aspect, the invention relates to a method for detecting a target short nucleic acid in a biological sample. The method includes contacting the biological sample with an aldehyde-containing fixative, and subsequently contacting the sample with a water-soluble carbodiimide. In a further aspect, the invention relates to a kit for fixing a short nucleic acid in a biological sample. The kit includes a support substrate for holding the sample; an aldehyde-containing fixative; and a water-soluble carbodiimide. | 2010-09-16 |
20100233707 | MATERIALS AND METHODS FOR PREDICTING RECURRENCE OF NON-SMALL CELL LUNG CANCER - Disclosed herein is a DNA methylation-based test for determining the recurrence or non-recurrence of a lung cancer such as NSCLC after treatment. The assays involve the detection of methylation of the BAX gene promoter alone or in combination with other genes. The test is suitable for monitoring treatment of subjects with lung cancer for which methylation differs by stage of the disease and by treatment regimen. | 2010-09-16 |
20100233708 | SPLIT FLOW DEVICE FOR ANALYSES OF SPECIFIC-BINDING PARTNERS - The present invention provides an analyte detection system for detecting a target analyte in a sample. In particular, the invention provides a detection system capable of one-step amplification of the detection signal by incorporating a secondary flow path that can deliver reagents to a reaction zone. Methods of using the detection system to detect analytes in samples, particularly biological samples, and kits comprising the detection system are also disclosed. | 2010-09-16 |
20100233709 | ABSCRIPTION BASED MOLECULAR DETECTION - The present invention provides methods for detecting biomarkers based on Abscription®, abortive transcription technology. Particularly, the present invention provides bisulfate free methods for detecting methylation of CpG islands from small samples of DNA. The methods are suitable for multiplexing and can be used to analyze multiple CpG islands from a single sample in a short time. | 2010-09-16 |
20100233710 | NUCLEIC ACID BINDING DYES AND USES THEREFOR - The invention provides novel compounds and compositions of Formulas I and II, as well as methods of using them. The compounds can be used, for example, to quantify an amount of double stranded DNA in a sample subjected to nucleic acid amplification, or for real time monitoring of a nucleic acid amplification reaction. The compounds can be provided in a kit, for example, with other reagents and instructions for using the compounds and reagents. | 2010-09-16 |
20100233711 | GENE ENCODING LABYRINTHIN, A MARKER FOR CANCER - A cDNA molecule that encodes a protein designated Labyrinthin (Lab) isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells. | 2010-09-16 |
20100233712 | Method for Early Detection of Cancers - The invention includes methods for detecting the presence of a neoplastic condition by comparing a sample level of a BIF-1 to a reference, wherein a low level of BIF-1 in the sample correlates with the presence of a neoplastic condition. Another method involves determining the risk of relapse, tumor recurrence and/or metastasis by determining a sample level of a Bif-1 to a reference level of Bif-1, wherein low sample levels correlate with a likelihood of relapse, recurrence and/or metastasis. Yet another method includes detecting the presence of a pre-neoplastic condition, such as prostatic intraepithelial neoplasia. The method involves measuring a level of a Bif-1 in a sample and comparing the level of Bif-1 in the sample to a reference level of Bif-1. High levels of Bif-1 in the sample correlate with the presence of the pre-neoplastic condition. | 2010-09-16 |
20100233713 | METHOD FOR TREATING A SOLUTION IN ORDER TO DESTROY ANY RIBONUCLEIC ACID AFTER AMPLIFICATION - The present invention provides a method for treating a solution containing among others, target nucleic acid to be amplified in order to destroy any ribonucleic acid that is present in the solution and that could possibly be amplified in another assay. The method is useful to avoid carry-over contamination between experiments. | 2010-09-16 |
20100233714 | MULTISTATE AFFINITY LIGANDS FOR THE SEPARATION AND PURIFICATION OF ANTIBODIES, ANTIBODY FRAGMENTS AND CONJUGATES OF - Separation of antibodies, antibody fragments, and conjugates thereof using multistate affinity ligands rationally designed and selected to undergo analytically and functionally definable conformational transitions from a first affinity state under a first operator-defined environmental condition to a second affinity state under a second operator-defined environmental condition. | 2010-09-16 |
20100233715 | METHOD OF NUCLEIC ACID AMPLIFICATION AND MEASURING REAGENT AND REAGENT KIT THEREFOR - The object of the present invention is to provide a method that allows stable amplification of an internal standard material while maintaining an accurate assay value for a target nucleic acid in a nucleic acid detection system involving the use of an internal standard material and a reagent kit used therefor. The present invention relates to a method for nucleic acid amplification comprising preventing an internal standard amplification product from affecting amplification reaction of a target nucleic acid by performing amplification of an internal standard material prior to amplification of the target nucleic acid in the method for amplifying a target nucleic acid in a sample using an internal standard material and a reagent and reagent kit used therefor. | 2010-09-16 |
20100233716 | TRANSPLANT REJECTION MARKERS - The invention relates to the analysis and identification of genes that are regulated simultaneously in chronic kidney transplant rejection. This simultaneous regulation of genes provides a molecular signature to accurately detect, and optionally classify, chronic kidney transplant rejection. | 2010-09-16 |
20100233717 | METHODS FOR DETECTING TOXIGENIC MICROBES - The present invention provides methods and oligonucleotides for detecting toxigenic microbes, such as toxigenic | 2010-09-16 |
20100233718 | NON-INVASIVE TECHNIQUE FOR CONDUCTING SKIN INFLAMMATORY DISEASE PHARMACO-GENOMIC STUDIES AND DIAGNOSES THEREOF - Non-invasive techniques to conduct skin inflammatory disease pharmaco-genomic studies and diagnoses thereof feature discriminating biomarkers and genes and in vitro diagnostic methods employing such biomarkers. | 2010-09-16 |
20100233719 | Genetic Markers for Predicting Disease and Treatment Outcome - The present invention provides for a method for identifying patients that are suitably treated by a therapy, such as a therapy involving administration of a fluoropyrimidine drug and/or a platinum drug. The method includes determining the expression level of at least one gene selected from a phospholipase 2 (PLA2) gene, a thymidine phosphorylase (TP) gene, and a glutathione S-transferase P1 (GSTP-1) gene in suitable sample isolated from the patient. Overexpression of the gene or genes identifies the patient as not being suitable for the therapy. | 2010-09-16 |
20100233720 | BIOLOGICAL REAGENTS AND METHODS TO VERIFY THE EFFICIENCY OF SAMPLE PREPARATION AND NUCLEIC ACID AMPLIFICATION AND/OR DETECTION - This invention relates to reagent comprising: any one of cells, viral particles, organelles, parasites, cells comprising organelles, cells comprising viral particles, cells comprising parasites, cells comprising bacterial cells and any combination thereof, the cells, viral particles, organelles or parasites comprising at least one nucleic acid sequence serving as an internal control (IC) target for nucleic acid testing (NAT) assay; wherein the reagent is suitable to be added to a test sample undergoing sample preparation to release, concentrate and/or purify nucleic acids and amplification and/or detection of nucleic acids so as to be used to verify: (i) the efficiency of sample preparation; and (ii) the efficiency of nucleic acid amplification and/or detection. The present invention also relates to a method to verify or validate the preparation and amplification and/or detection of a nucleic acid target sequence in a sample spiked with a reagent of the present invention. | 2010-09-16 |
20100233721 | APPARATUS AND METHODS FOR DETECTING DNA IN BIOLOGICAL SAMPLES - Apparatus and methods are described for detecting target DNA in a biological sample using capture probes and electrically-assisted hybridization. The reaction cell is formed with an attachment surface of aluminum oxide for better thermal and physical properties, and the aluminum oxide surface is coated with anti-DIG antibody to provide a convenient attachment layer for the capture probes allowing their correct orientation, while the capture probes are formed with a DIG-label so that they attach to the surface of the cell through an anti-DIG/DIG linkage. | 2010-09-16 |
20100233722 | Methods for determining the biological effect and/or activity of r pharmaceutical compositions based on their effect on the methylation status of the DNA - This invention is related to methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions using their effect on DNA methylation as a marker for their biological effect(s). The invention is further related to the use of the inventive methods, systems and computer program products in obtaining new biologically active compounds for new and effective medicaments and treatment strategies of, in particular, human diseases. | 2010-09-16 |
20100233723 | DRY STICK DEVICE AND METHOD FOR DETERMINING AN ANALYTE IN A SAMPLE - The present invention relates to a dry stick test device for the determination of an analyte in a sample by means of a chemical assay. The device comprises: (i) optionally a solid support, (ii) at least one reagent pad comprising a reagent capable of reacting with the analyte, a derivative of said analyte or an indicator compound for said analyte to provide a detectable signal when in moistened state, and (iii) a development pad which is located in contact with the at least one reagent pad, optionally between the solid support and the at least one reagent pad, said development pad comprises at least one controlling compound capable of providing a condition required for the reagent to react with the analyte to provide a detectable signal, wherein the at least one reagent pad and the development pad are arranged to avoid precipitation of sample component(s) on the top-face of the device. | 2010-09-16 |
20100233724 | MARKERS OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND METHODS OF USE THEREOF - Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH. | 2010-09-16 |
20100233725 | IMMUNOASSAYS EMPLOYING NON-PARTICULATE CHEMILUMINESCENT REAGENT - Methods and reagents are disclosed for conducting assays. Embodiments of the present methods and reagents are concerned with chemiluminescent reagents for determining the presence and/or amount of an analyte in a sample suspected of containing the analyte. The reagent is non-particulate and comprises a binding partner for the analyte and a chemiluminescent composition comprising an olefinic compound and a metal chelate. In embodiments of an assay, a combination is provided that comprises a sample suspected of containing the analyte, a chemiluminescent reagent as described above and a sensitizer reagent capable of generating singlet oxygen. The combination is subjected to conditions for binding of the analyte to the binding partner for the analyte. The sensitizer is activated and the amount of luminescence generated by the chemiluminescent composition is detected wherein the amount of luminescence is related to the amount of the analyte in the sample. | 2010-09-16 |
20100233726 | TANDEM FLUORESCENT PROTEIN CONSTRUCTS - This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays. | 2010-09-16 |
20100233727 | MARKER FOR ARRHYTHMIA RISK - The present invention relates to markers and methods for determining risk of ventricular arrhythmia in an African American or woman patient. By using the markers of the present invention, individual with high risk of ventricular arrhythmia can properly be detected and treated. The present inventors have discovered that, in African American and women, IL-6 and/or DROMs and/or CRP have strongly positive correlation with the risk of ventricular arrhythmia. | 2010-09-16 |
20100233728 | METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 2010-09-16 |
20100233729 | DETECTING INTERACTIONS AT BIOMIMETIC INTERFACES WITH LIQUID CRYSTALS - A method of forming a liquid crystal device, includes: contacting an aqueous solution comprising a surfactant and a receptor molecule with a top surface of a liquid crystal. The liquid crystal is in a holding compartment of a substrate, and the receptor molecule is adsorbed on the top surface of the liquid crystal forming an interface between the liquid crystal and the aqueous solution. The receptor molecule is different than the surfactant. A method of detecting a compound in a flowing stream includes passing an aqueous solution over a top surface of a liquid crystal in a holding compartment of a substrate. The method also includes determining whether a change in the orientation of the liquid crystal occurs as the aqueous solution is passed over the top surface of the liquid crystal. A change in the orientation of the liquid crystal indicates the presence of the compound in the flowing stream. | 2010-09-16 |
20100233730 | THERAPEUTIC MODULATION OF AUTOPHAGY - Methods for screening for modulators of autophagy are disclosed. Methods for identifying genes whose expression inhibits autophagy, as well as genes whose expression promotes autophagy, are disclosed. Also disclosed are methods for identifying compounds that stimulate autophagy, as well as compounds that inhibit autophagy. Cell lines that may be used in the methods of identification are also disclosed. | 2010-09-16 |
20100233731 | DETECTION AND MEASUREMENT OF BLOOD-FEEDING ACTIVITY - This invention provides compositions and methods for detection of hematophagous ectoparasitic activity in an enclosure or area. The compositions comprise a reagent or reagents which are reactive against antigens or markers as they appear in the excrement or other ectoparasitic materials. Such markers or antigens may be produced by the ectoparasite itself or may have been introduced into the ectoparasite because of its blood feeding activity. The method of the present invention comprises collecting from the enclosure or area, a sample comprising environmental dust or materials and subjecting the sample to tests for detecting the presence of hematophagous ectoparasitic markers, host markers or both. | 2010-09-16 |
20100233732 | Methods of Determining Patient Response By Measurement of HER-2 Expression - Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial. | 2010-09-16 |
20100233733 | MULTIPLE MECHANISMS FOR MODULATION OF THE PI3 KINASE PATHWAY - An embodiment of the present invention is a method for measuring the post translational states and expression levels of proteins in the PI3K and/or mTor for use in diagnosis, prognosis and drug screening applications. | 2010-09-16 |
20100233734 | PASSIVATION OF SURFACES AFTER LIGAND COUPLING - Passivated substrates are provided for use in assays, comprising at least one covalently bonded ligand having specific binding activity for a molecule, and at least one covalently bonded blocking agent, wherein said ligand is directly bonded to the substrate surface. In certain embodiments, the ligand and blocking agent are covalently bonded only to the substrate surface, and not directly bonded to each other. In certain other embodiments, the ligand and blocking agent have at least one additional covalent bond to one another. Methods for preparing and using passivated substrates in bioassays are also provided. | 2010-09-16 |
20100233735 | PHARMACEUTICALS AND METHODS FOR TREATING HYPOXIA AND SCREENING METHODS THEREFOR - Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions. | 2010-09-16 |
20100233736 | DETECTION METHOD AND KIT - The present invention relates to a method of detection and/or quantification of an antigen linked to a metal salt. The antigen may be present within a mixture of different antigens, such as in a multivalent vaccine composition. The invention further provides a kit for use in the method of the invention. | 2010-09-16 |
20100233737 | MARKER SPECIFIC TO AN OXIDATIVE DEGRADATION OF TISSUES CONTAINING TYPE III COLLAGEN, MEANS AND METHODS AND KITS FOR THE DIAGNOSIS, MONITORING OR PROGNOSIS OF PATHOLOGIES TARGETED BY THIS MARKER - Novel peptide marker, specific to the oxidative degradation of tissues containing type III collagen, preferably to nitrosylation of the type III collagen. This marker is defined of at least one peptide sequence of 5 to 25 amino acids (AAs) including a sub-sequence QYDSYD in which at least one of the Ys is nitrosylated and Q corresponds not only to glutamine but also to pyroglutamic acid. This marker is simple, sensitive and reliable and expedites the clinical information for obtaining oxidative degradation of tissues containing type III collagen (O.D.T.Coll III) pathologies. This marker allows better monitoring, prognosis and treatment of the O.D.T.Coll III pathologies. This invention concerns also elements of detection of the marker, methods and kits which allow, on one hand, the early, reliable, efficient and economical diagnosis of the pathologies targeted and, on the other hand, improved monitoring and prognosis of the O.D.T.Coll III pathologies. | 2010-09-16 |
20100233741 | IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS - The present specification discloses SNAP-25 immune response inducing compositions, methods of making α-SNAP-25 antibodies that selectively binds to an epitope comprising a SNAP-25 having a carboxyl-terminus at the P | 2010-09-16 |
20100233742 | Method of Quantifying Autoinducer-2 - A method of quantifying autoinducer-2, including the steps of:
| 2010-09-16 |
20100233743 | BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES - This invention relates to fluorescent probes for identification of compounds binding to protein kinases, for measurement of the affinity of inhibitors of protein kinases, and determination of the active concentration of protein kinases binding to the probe. Bisubstrate-analog character of the probe enables the simultaneous evaluation of inhibitors targeted to both ATP binding site and/or substrate protein/peptide binding domain of the kinase. High affinity of the probe (K | 2010-09-16 |
20100233744 | Enzyme substrates for visualizing acidic organelles - The present invention relates to the visualization of acidic organelles based upon organelle enzyme activity. The organelle substrates of the invention are specific for enzyme activity of the organelle and label these organelles, such as lysosomes, rendering them visible and easily observed. Substrates of the present invention include substrates that produce a fluorescent signal. The fluorogenic acidic organelle enzyme substrates of this invention are designed to provide high fluorescence at low pH values and are derivatized to permit membrane permeation through both outer and organelle membranes of intact cells and can be used for staining cells at very low concentrations. They can be used for monitoring enzyme activity in cells at very low concentrations and are not toxic to living cells or tissues. | 2010-09-16 |
20100233745 | DETECTING A MICROORGANISM STRAIN IN A LIQUID SAMPLE - The invention concerns a medium for detecting, identifying and differentiating a microorganism strain in a liquid medium by contacting said liquid sample with a combination of chromogens substrates of enzymes expressed or not by the strain to be detected, the final coloration of the mixture being detectable in the wavelengths of the visible light. | 2010-09-16 |
20100233746 | Inflammation and Oxidative Stress Level Assay - The present invention relates to a method for determining the systemic metabolic status of an organism in relation to inflammation and oxidative stress using a biological sample (Inflammation and Oxidative Stress Level Assay). This comprises detection and quantification of one or more derivatives of arachidonic acid (eicosanoids), linoleic acid and/or docosahexaenoic acid, preferably together with one or more oxidative stress parameters and/or with one or more analytes from other metabolite classes in parallel, as well as a kit adapted for carrying out such a method. Moreover, the invention relates to the biomarkers as employed in the method. | 2010-09-16 |
20100233747 | METHOD AND MEANS FOR THE ENZYMATIC DETERMINATION OF ETHANOL - The invention relates to a method and means for the enzymatic determination of ethanol. The method according to the invention prevents ethanol vapours in the ambient air from interfering with the determination. | 2010-09-16 |
20100233748 | Device with biological component and method of making to achieve a desired transfer function - An improved method for the design and development of high performance hybrid devices having biologically-derived and nonbiological components and the hybrid devices so-designed and developed. A desired transfer function is determined for the biologically-derived component or components. The organism from which the biologically-derived component is derived is subjected to various environmental variables as it is grown. Organisms providing biologically-derived components having the desired transfer function are identified. The biologically-derived component is thereafter developed from organisms force adapted to cause the biologically-derived component transfer function to reach a goal or an acceptable measure. The biological component is used in hybrid constructs that may be nanostructures, given the small size of the biological parts. In one specific embodiment, force-adapted chlorosomes of | 2010-09-16 |
20100233749 | Device with biological component and method of making to achieve a desired figure of merit - An improved method for the design and development of high performance hybrid devices having biologically-derived and nonbiological components and the hybrid devices so-designed and developed. A desired figure of merit is determined for the biologically-derived component or components. The organism from which the biologically-derived component is derived is subjected to various environmental variables as it is grown. Organisms providing biologically-derived components having the desired figure of merit are identified. The biologically-derived component is thereafter developed from organisms force adapted to cause the biologically-derived component figure of merit to reach a goal or an acceptable measure. The biological component is used in hybrid constructs that may be nanostructures, given the small size of the biological parts. In one specific embodiment, force-adapted chlorosomes of | 2010-09-16 |
20100233750 | Human Blood Brain Barrier Model - The present invention relates to an immortalized human brain endothelial cell line that is useful as an in vitro model of the blood brain barrier. | 2010-09-16 |
20100233751 | APPARATUS AND METHOD FOR MONITORING CULTURES - Disclosed is a bubble excluder device ( | 2010-09-16 |
20100233752 | METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES - The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus and drug-induced lupus erythematosus by measuring cell-based complement activation products in a subject's blood. In particular, the invention describes a diagnostic method employing the measurement of multiple complement activation products, such as C3 | 2010-09-16 |
20100233753 | OPTICAL MEASURING DEVICE AND METHOD THEREFOR - The light measurement apparatus of the invention, in which the light is irradiated to the sample dispersed in the liquid flowing through the flow passage, is used for measuring optical information of the sample. The apparatus includes a light source portion | 2010-09-16 |
20100233754 | Vessel Transporting Apparatus and Method - This disclosure relates to an apparatus for transporting a vessel and to a sorting apparatus. The apparatus has at least one support device adapted to support the vessel in a reclined orientation, and a pushing mechanism adapted to transport the vessel along the support device. Advantageously, the apparatus is relatively simple and does not require vessels to contact an endless conveyor. Thus, vessels can be more readily rotated, weighed, etc. This disclosure also relates to a method of sorting vessels. One application of the apparatus and method is in the sorting of test tubes containing blood samples for testing. | 2010-09-16 |
20100233755 | PDX1-EXPRESSING DORSAL AND VENTRAL FOREGUT ENDODERM - Disclosed herein are cell cultures comprising dorsal and/or ventral PDX1-positive foregut endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified dorsal and/or ventral PDX1-positive foregut endoderm cells as well as methods for enriching, isolating and purifying dorsal and/or ventral PDX1-positive foregut endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells, are also disclosed. | 2010-09-16 |
20100233756 | Animal Feed Kibble with Protein-Based Core and Related Methods - Kibble-type animal feeds and pet foods including a vegetable protein-based core matrix and a coating of a fat and at least one additive are described. The coating may include a probiotic enriched coating. Methods of forming the kibble-type animal feeds and pet foods are also described. Probiotic coating for a kibble showing acceptable stability and bioactivity are disclosed and methods for assessing the bioactivity of a probiotic in a food composition are also described. | 2010-09-16 |
20100233757 | Synthesis and Use of Anti-Reverse Phosphorothioate Analogs of the Messenger RNA Cap - New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2′-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are “anti-reverse cap analogs” (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five-fold more efficiently than mRNAs synthesized with the conventional analog m | 2010-09-16 |
20100233758 | Protein increasing cell infectivity of herpes simplex virus and use thereof - Provided are an isolated protein derived from an N-terminal of HveA/HVEM and having activity of increasing the cell infectivity of herpes simplex virus (HSV) and use thereof. | 2010-09-16 |
20100233759 | METHOD FOR PRODUCTION OF POLYPEPTIDE - The present invention provides a method capable of producing a natural or recombinant protein in high yield. | 2010-09-16 |
20100233760 | Protein Production in Microorganisms of the Phylum Labyrinthulomycota - The present invention relates to recombinant cells and microorganisms of the phylum Labyrinthulomycota and their use in heterologous protein production. Novel promoter, terminator, and signal sequences for efficient production and, optionally, secretion of polypeptides from recombinant host cells and microorganisms are also encompassed by the present invention. | 2010-09-16 |
20100233761 | ALGAE BIOMASS FRACTIONATION - A method of fractionating biomass, by permeability conditioning biomass suspended in a pH adjusted solution of at least one water-based polar solvent to form a conditioned biomass, intimately contacting the pH adjusted solution with at least one non-polar solvent, partitioning to obtain an non-polar solvent solution and a polar biomass solution, and recovering cell and cell derived products from the non-polar solvent solution and polar biomass solution. Products recovered from the above method. A method of operating a renewable and sustainable plant for growing and processing algae. | 2010-09-16 |
20100233762 | THERMOSTABLE Y-FAMILY POLYMERASES AND CHIMERAS - The present disclosure is related to thermostable Y-family polymerases, in particular several novel Y-family polymerases and chimeras made therefrom, as well as methods of identifying other Y-family polymerases, methods of generating other chimeric Y-family polymerases, methods of amplifying ancient or damaged DNA, and methods of incorporating fluorescent or modified nucleotides into a DNA molecule. | 2010-09-16 |
20100233763 | DUAL-SIDED THERMAL CYCLER - A device, system, and method are provided for thermally treating a fluid processing device. According to various embodiments, a system is provided that can include a thermal device and a fluid processing device holder. The thermal device can include a first block having a thermal conductivity greater than 0.5 Watt per centimeter Kelvin (W/cm·K), a second block having a thermal conductivity greater than 0.5 W/cm·K, and a heat-pump device disposed between the first block and the second block. The heat-pump device can transfer thermal energy from at least one of the first block and the second block to the other of the first block and the second block. The fluid processing device holder can hold a fluid processing device in a heat-transfer position with respect to the first block and the second block. The fluid processing device can be a microfluidic device. | 2010-09-16 |
20100233764 | Process for Producing Poly-y-Glutamic Acid Having High Optical Purity - It is an objective of the present invention to provide a process for efficiently producing poly-γ-glutamic acid having a high L-glutamic acid content and excellent quality. The process for producing poly-γ-glutamic acid according to the present invention is characterized in using a bacterium belonging to species | 2010-09-16 |
20100233765 | L-CYSTEINE-PRODUCING BACTERIUM AND A METHOD FOR PRODUCING L-CYSTEINE - The present invention provides a bacterium belonging to the family Enterobacteriaceae, which is able to produce L-cysteine, and has been modified to decrease activity of the YdjN protein, or the activities of the YdjN and the FliY protein. This bacterium is cultured in a medium, and L-cysteine, L-cystine, a derivative or precursor thereof, or a mixture of these can be collected from the medium. | 2010-09-16 |
20100233766 | Novel Microorganism and Method for Producing Dodecahydro-3a,6,6,9a-Tetramethylnaphtho[2,1-b]Furan Intermediate Using the Novel Microorganism - This invention relates to a novel microorganism that efficiently produces a dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan intermediate using sclareol as a substrate. As a result of concentrated studies, a plurality of novel microorganisms having properties of interest that are not classified as conventional microorganisms were isolated and identified. The novel microorganism of the present invention belongs to Ascomycetes and has the ability of producing a dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan intermediate using sclareol as a substrate. Such microorganism of Ascomycetes represents a new finding and it can be effective for producing dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan and an intermediate thereof. | 2010-09-16 |
20100233767 | PROCESS FOR THE RECOVERY OF MAGNESIUM FROM A SOLUTION AND PRETREATMENT - A process for the recovery of magnesium from a solution containing soluble magnesium, the process comprising, precipitating magnesium hydroxide from the solution, forming an oxide blend including magnesium oxide derived from the precipitated magnesium hydroxide together with calcium oxide, reducing the oxide blend to form a magnesium metal vapour and condensing the vapour to recover magnesium metal. | 2010-09-16 |
20100233768 | METHOD FOR ISOLATING POLYHYROXYALKANOATES - The invention relates to a method for isolating polyhydroxyalkanoates from production cells which comprises | 2010-09-16 |
20100233769 | Biomass treatment process - A process for the treatment of biomass is provided. The process comprises forming a biomass slurry by mixing biomass with a working fluid, and inducing the biomass slurry to flow through an inlet into a passage. A high velocity transport fluid is injected into the slurry through a nozzle communicating with the passage. The injection of the high velocity transport fluid applies a shear force to the slurry such that the working fluid is atomised and forms a vapour and droplet flow regime, an at least partial vacuum is formed within the passage downstream of the nozzle, and a condensation shock wave is generated within the passage downstream of the nozzle and vacuum by condensation of the transport fluid. An apparatus for treating biomass using the aforementioned process is also provided. | 2010-09-16 |
20100233770 | METHOD OF CONTINUOUSLY PRODUCING ETHANOL AND ELECTRICITY FROM A SUSTAINABLE RENEWABLE BIOMASS FEEDSTOCK - Disclosed is a method of continuously producing ethanol and electricity from a sustainable renewable biomass feedstock in a processing plant contiguous to the acreage providing the biomass. The process is a closed loop operation having a dedicated crop grown year round producing multiple crops per acre. The renewable biomass feedstock is a sugar containing feedstock such as sweet sorghum. The biomass is grown year round and produces multiple crops per acre. | 2010-09-16 |
20100233771 | SYSTEM FOR PRE-TREATMENT OF BIOMASS FOR THE PRODUCTION OF ETHANOL - A system for the pre-treatment of biomass for use in a biorefinery to produce ethanol and other bioproducts is disclosed. The system comprises a method comprising the steps of preparing the biomass into prepared biomass; pre-treating the prepared biomass into pre-treated biomass by application of a dilute acid having a concentration of about 0.8 to 1.1 percent by weight at a temperature of about 130 to about 170 degrees Celsius for a period of time in a range of about 8 to 12 minutes. The system also comprises an apparatus for separating the pre-treated biomass into a liquid component comprising pentose and a solids component comprising cellulose and lignin; a fermentation system configured to produce the fermentation product; and a distillation system. The fermentation product comprises ethanol. The biomass comprises lignocellulosic material, comprising corn cobs, corn plant husks, corn plant leaves and corn plant stalks. | 2010-09-16 |
20100233772 | MODULAR SYSTEM FOR INTRODUCING A STREAM OF PROCESSED GRAIN INTO AN ETHANOL PRODUCTION FACILITY, AND ASSOCIATED METHODS - A modular system is provided to introduce a grain containing a commercial enzyme into an ethanol production facility. The modular system comprises a plurality of portable storage units configured to receive a raw grain material. Each storage unit is adapted for transportation between ethanol production facilities. A portable processing unit is in communication with each of the storage units for receiving the grain material therefrom. The processing unit is configured to mix a grain containing a commercial enzyme with a commodity grain so that the enzyme is in effective amounts to sufficiently carry out downstream enzymatic applications. The processing unit is further configured to meter the processed grain material at appropriate admix levels to an ethanol production facility. The processing unit is adapted for transportation between ethanol production facilities. Associated apparatuses and methods are also provided. | 2010-09-16 |
20100233773 | Saccharifying Cellulose - Dissolution, partial dissolution or softening of cellulose in an ionic liquid (IL) and its subsequent contact with anti-solvent produces regenerated cellulose more amorphous in structure than native cellulose, which can be separated from the IL/anti-solvent mixture by mechanical means such as simple filtration or centrifugation. This altered morphology of IL-treated cellulose allows a greater number of sites for enzyme adsorption with a subsequent enhancement of its saccharification. The IL-treated cellulose exhibits significantly improved hydrolysis kinetics with optically transparent solutions formed after about two hours of reaction. This provides an opportunity for separation of products from the catalyst (enzyme) easing enzyme recovery. With an appropriate selection of enzymes, initial hydrolysis rates for IL-treated cellulose were up to two orders of magnitude greater than those of untreated cellulose. Due to the non-volatility of the IL, anti-solvent can be easily stripped from the IL/anti-solvent mixture for recovery and recycle of both the ionic liquid and anti-solvent. | 2010-09-16 |
20100233774 | Circulatory Biomass Energy Recovery System and Method - A circulatory biomass energy recovery system and method raising an energy recovery efficiency are provided. The circulatory biomass energy recovery system has a culture unit | 2010-09-16 |
20100233775 | System for the production of methane and other useful products and method of use - A system for the production of methane and other useful products and method of use for generating green natural gas as a fuel or component for use in the manufacturing of specialty chemicals. The system for the production of methane and other useful products and method of use includes a culture of methanogenic archea for converting an input material into an output material, a reactor vessel for housing at least a portion of the culture of methanogenic archea, an input material stream directed into the reactor vessel to facilitate contact between the input material stream and the methanogenic archea, and an output material stream created at least in part by the culture of methanogenic archea. | 2010-09-16 |
20100233776 | NOVEL HYDROGEN-PRODUCING BACTERIUM - The present invention aims to provide a hydrogen-producing bacterium, which excels in hydrogen yield and hydrogen production rate, and is usable for industrial hydrogen production from biomass as a production source. That is, it is intended to provide a bacterium belonging to the genus | 2010-09-16 |